Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Senesco Presents Pre-Clinical Multiple Myeloma Data At The 12th Annual Meeting Of The American Society Of Gene Therapy
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco"s multiple myeloma studies at the 12th Annual Meeting of the American Society of Gene Therapy, which is being held at the San Diego Convention Center in San Diego, CA, from Wednesday, May 27th through to Saturday, May 30th, 2009. Mr. Dondero will be presenting in the afternoon session on Thursday, May 28th.
generic viagra online
Lawmakers Seek Price Tag They Can Agree On
"Lawmakers working to overhaul the U.S. health-care system face a pressure-filled July after leaving town this week without resolving the biggest questions dividing Democrats and Republicans," Bloomberg reports. Democrats on the Senate Finance Committee - which observers deem most likely to come up with a passable, bipartisan bill - have been working to reduce the cost of the overhaul to gain Republican support, but had not yet released a proposal. Bloomberg adds: "While the Congressional Budget Office said options under consideration by the committee can keep the cost within Baucus"s goal of $1 trillion over 10 years, how to pay for the plan remains unsettled. So is structuring some kind of government-run competition for insurers. ... "Nothing has been set," Montana Democrat [Max] Baucus told reporters in the Capitol on June 25. The recess offers a chance for "taking stock," he said" (Jensen and Livkin, 6/29).
News of the day
Side Discrepancy Errors In Radiology Reports Rare But Often Clinically Significant
Side discrepancy errors in radiology reports do occur and it is important that radiologists, referring physicians and patients communicate well to help prevent errors in clinical management, according to a study performed at Massachusetts General Hospital, Boston, MA. "Side discrepancy errors refer to instances when the side of the lesion is incorrectly noted in one or more sections of the radiology report," said Minal Jagtiani Sangwaiya, MD, lead author of the study.
Medical Devices

Teva And Antares Announce FDA Approval Of Needle-Free Injector Product For Administration Of Tev-Tropin(R) (Human Growth Hormone)

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and its partner, Antares Pharma, Inc. (NYSE Amex: AIS) announced the approval of a Supplemental New Drug Application (sNDA), which added "needle-free injection" to its Tev-Tropin® [somatropin (rDNA) for injection] brand human growth hormone (hGH) drug label. Teva will market the Antares needle-free device as the Tev-Tropin Tjet Injector system. "We are pleased to add this new technology to our growing portfolio through our successful partnership with Antares, and to offer patients a less invasive delivery system," stated Larry Downey, head of Teva"s North America Brand Pharmaceuticals division. "This significant achievement demonstrates our ability to leverage our leadership in the pharmaceutical industry, and our ongoing commitment to utilize our global strengths in innovative activities." "This is the first product approval stemming from our portfolio of product collaborations with Teva and is a very exciting milestone for the Company" said Paul K. Wotton, President and Chief Executive Officer of Antares Pharma. "Importantly it is another example of delivering on our strong focus and commitment to patients, together with our partners, to provide new ways to administer drugs. We look forward to the launch of this product by Teva." Human growth hormone is a protein given by injection that is commonly used to treat children with growth hormone deficiency. Pediatric patients benefit both from the avoidance of using needles as well as the rapid injection speed associated with giving needle-free injections. According to industry estimates, the market for human growth hormone in the United States is approximately $1 billion which is the largest market segment globally. Antares currently markets its needle-free injection system for use in the treatment of growth hormone deficient children through its partners in Europe, Japan and Asia. Tev-Tropin®


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009